A favourable benefit/risk ratio with efalizumab: A review of the clinical evidence

Journal of Cutaneous Medicine and Surgery

Volumn 9, Issue SUPPL. 1, 2005, Pages 10-17

  Poulin, Yves ^a,e   Papp, Kim A ^b   Carey, Wayne ^c   Gulliver, Wayne ^d   Gupta, Aditya K ^e,f  

^a UNIVERSITÉ LAVAL   (Canada)

^b PROBITY MEDICAL RESEARCH   (Canada)

^c ROYAL VICTORIA HOSPITAL   (Canada)

^d University of Toronto ^*  (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f MEDIPROBE RESEARCH INC   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; EFALIZUMAB; METHOTREXATE;

ABSCESS; ASEPTIC MENINGITIS; ASTHENIA; BACKACHE; BRONCHITIS; CANCER; CELLULITIS; CHILL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COUGHING; DEMYELINATING DISEASE; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEVER; FLU LIKE SYNDROME; GASTROENTERITIS; GRANULOMATOSIS; HEADACHE; HUMAN; INFECTION; LARYNX SPASM; LEGIONNAIRE DISEASE; LONG TERM CARE; MYALGIA; NAUSEA; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; PSORIASIS VULGARIS; RASH; REBOUND; REVIEW; RHINITIS; RISK BENEFIT ANALYSIS; SEPSIS; SINUSITIS; SPONDYLITIS; T LYMPHOCYTE; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUBERCULOSIS;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD11; BODY SURFACE AREA; CLINICAL TRIALS; HUMANS; IMMUNOLOGIC FACTORS; PSORIASIS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 33747367988     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10227-006-0102-2     Document Type: Review

References (24)

1. Cather JC, Menter A. Efalizumab: Continuous therapy for chronic psoriasis. Expert Opin Biol Ther 2005; 53:393-403.
2. Leonardi CL. Current concepts and review of efalizumab in the treatment of psoriasis. Dermatol Clin 2004; 22:427-435.
3. Wellington K, Perry CM. Efalizumab. Am J Clin Dermatol 2005; 62:113-118.
4. Cather JC, Cather JC, Menter A. Modulating T-cell responses for the treatment of psoriasis: a focus on efalizumab. Expert Opin Biol Ther 2003; 32:361-370.
5. Della Croce C, Kwan Wong V, Lebwohl MG. Efalizumab in the treatment of psoriasis. Therapy 2004; 12:197-202.
6. Shear NH, Langley RG, Ho V. Efalizumab, a reversible T-cell modulator for psoriasis. J Cutan Med Surg 2005; This supplement.
7. Raptiva® (efalizumab) Canadian Prescribing Information. Serono Canada, Inc. 2005.
8. Papp KA, Toth DP. Safety and efficacy of efalizumab retreatment: Final results from an open-label study in psoriasis. Presented at the 13th Congress of the European Academy of Dermatology and Venereology. November 17-21, 2004; Florence, Italy. Poster #74.
9. Leonardi CL. Efalizumab: an overview. J Am Acad Dermatol 2003; 49:S98-104.
10. Gordon KB, Papp KA, Hamilton TK, et al. Efalizumab for patients with moderate to severe plaque psoriasis. JAMA 2003; 290:3073-3080.
11. Gottlieb AB, Gordon KB, Lebwohl MG, et al. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J Drugs Dermatol 2004; 36:614-624.
12. Gottlieb A, Gordon K, Hamilton T, et al. Maintenance of Efficacy and Safety with Continuous Efalizumab Therapy in Patients with Moderate to Severe Chronic Plaque Psoriasis: Final Phase IIIb Study Results. Presented at the 63rd Annual Meeting of the American Academy of Dermatology. New Orleans; 2005. Poster #4.
13. Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell moderator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349:2004-2013.
14. Menter A, Gordon K, Carey W, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005; 141:31-38.
15. Leonardi CL, Papp KA, Gordon KB. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 2005; 52:425-433.
16. Sterry W, Dubertret L, Papp K, et al. Efalizumab for patients with moderate to severe chronic plaque psoriasis: Results of the international, randomized, controlled phase III Clinical Experience Raptiva (CLEAR) trial. Presented at the 34th Annual ESDR Meeting. September 9-11, 2004. Vienna, Austria. Poster #386.
17. Carlin CS, Feldman SR, Krueger JG, et al. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004; 50:859-866.
18. Stone S, Papp KA, Caro I, et al. Interpretation of positive patient response to efalizumab for the treatment of moderate to severe plaque psoriasis. Presented at the 13th Congress of the European Academy of Dermatology and Venereology. November 17-21, 2004; Florence, Italy. Poster #610.
19. Menter A, Kardatzke D, Rundle AC et al. Incidence and prevention of rebound upon efalizumab discontinuation. Poster presentation at the 11th International Psoriasis Symposium. June 15-18, 2005; Toronto, Canada.
20. Papp KA, Toth D, Rosolph L. Approaches to discontinuing efalizumab: Results of an open-label study comparing different transitioning therapies. Presented at the 3rd European Academy of Dermatology and Venereology Spring Symposium, Sofia, Bulgaria, May 19-22, 2005. Poster #PDT9.
21. Carey W, Rundle AC, Kwon P, Leonardi CL. Taper regimens in the management of patients discontinuing efalizumab therapy. Presented at the 11th International Psoriasis Symposium. June 14-19, 2004; Toronto, Canada. Poster #29.
22. Papp K. Patient management in psoriasis treatment using efalizumab. J Cutan Med Surg 2005; This supplement.
23. Carey W, Toth DP, Bissonnette R et al. No evidence for increased risk of infection during efalizumab treatment: A review of the clinical data. Presented at the 13th Congress of the European Academy of Dermatology and Venereology. November 17-21, 2004; Florence, Italy. Poster #79.
24. Toth DP, Carey W, Bissonnette R et al. Risk of malignancy during efalizumab treatment: A review of the clinical data. Presented at the 13th Congress of the European Academy of Dermatology and Venereology. November 17-21, 2004; Florence, Italy. Poster #110.